This is a summary of the European public assessment report (EPAR) for Vipidia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vipidia. For practical information about using Vipidia, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
Therapeutic Area (MeSH)
N/AATC Code
A10BH04
ATC Item
alogliptin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| alogliptin | N/A | 阿格列汀 |
EMA Name
Vipidia
Medicine Name
Vipidia
Aliases
N/ANo risk management plan link.
